Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Elanco Animal Health Incorporated (NYSE:ELAN) reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a ...

Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco Animal Health (NYSE:ELAN) traded lower in the premarket on Tuesday after the veterinary product maker, with its Q4 2024 results, set its full-year outlook below consensus, citing an unfavorable ...

Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.

Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.

Elanco Animal Health (NYSE:ELAN – Get Free Report) is anticipated to announce its earnings results before the market opens on ...

Elanco Animal Health (ELAN) has received a warning letter from the FDA related to promotional materials for its canine drug ...